{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T05:55:02Z","timestamp":1778738102138,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,11]]},"DOI":"10.7759\/cureus.24029","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:08:15Z","timestamp":1649678895000},"source":"Crossref","is-referenced-by-count":2,"title":["Drug Use Evaluation of Direct Oral Anticoagulants (DOACs) in Patients With Advanced Cirrhosis"],"prefix":"10.7759","author":[{"given":"Apaar","family":"Dadlani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lindsey","family":"Kays","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeepthi","family":"Bandikatla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regan","family":"Wade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashutosh","family":"Barve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02358.x","article-title":"Low-molecular-weight heparin in patients with advanced cirrhosis","volume":"31","author":"Bechmann LP","year":"2011","unstructured":"Bechmann LP, Sichau M, Wichert M, Gerken G, Kr\u00f6ger K, Hilgard P. Low-molecular-weight heparin in patients with advanced cirrhosis. Liver Int. 2011, 31:75-82. 10.1111\/j.1478-3231.2010.02358.x","journal-title":"Liver Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14309\/01.ajg.0000787128.55720.2c","article-title":"Evaluation of the use of direct oral anticoagulants in patients with cirrhosis (Abstract)","volume":"116","author":"Dadlani A","year":"2021","unstructured":"Dadlani A, Kays L, Wade R, Bandikatla S, Barve A. Evaluation of the use of direct oral anticoagulants in patients with cirrhosis (Abstract). Am J Gastroenterol. 2021, 116:S1398. 10.14309\/01.ajg.0000787128.55720.2c","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.15761\/JTS.1000182","article-title":"Hemostasis, bleeding and thrombosis in liver disease","volume":"3","author":"Flores B","year":"2017","unstructured":"Flores B, Trivedi HD, Robson SC, Bonder A. Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci. 2017, 3:10.15761\/JTS.1000182","journal-title":"J Transl Sci"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0034-0","article-title":"Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment","volume":"52","author":"Graff J","year":"2013","unstructured":"Graff J, Harder S. Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment. Clin Pharmacokinet. 2013, 52:243-54. 10.1007\/s40262-013-0034-0","journal-title":"Clin Pharmacokinet"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00775-z","article-title":"Apixaban: a clinical pharmacokinetic and pharmacodynamic review","volume":"58","author":"Byon W","year":"2019","unstructured":"Byon W, Garonzik S, Boyd RA, Frost CE. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019, 58:1265-79. 10.1007\/s40262-019-00775-z","journal-title":"Clin Pharmacokinet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.2008.283","article-title":"Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment","volume":"85","author":"Frost CE","year":"2009","unstructured":"Frost CE, Yu Z, Wang J, et al.. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther. 2009, 85:S34 (PI-84). 10.1038\/sj.clpt.2008.283","journal-title":"Clin Pharmacol Ther"},{"key":"ref7","article-title":"ELIQUIS\u00ae (apixaban). Package Insert. Bristol-Myers Squibb Co, Pfizer Inc","year":"2021","unstructured":"ELIQUIS\u00ae (apixaban) (Package Insert). Pfizer Inc., New York, United States; 2021. https.\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf."},{"key":"ref8","article-title":"XARELTO\u00ae (rivaroxaban). Package Insert. Janssen Pharmaceuticals, Inc","year":"2021","unstructured":"XARELTO\u00ae (rivaroxaban) (Package Insert). Janssen Pharmaceuticals, Inc., Titusville, New Jersey; 2021. https.\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/XARELTO-pi.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0100-7","article-title":"Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban","volume":"53","author":"Mueck W","year":"2014","unstructured":"Mueck W, Stampfuss J, Kubitza D, Becka M. Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet. 2014, 53:1-16. 10.1007\/s40262-013-0100-7","journal-title":"Clin Pharmacokinet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27350","article-title":"Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis","volume":"61","author":"Potze W","year":"2015","unstructured":"Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis. Hepatology. 2015, 61:1435-6. 10.1002\/hep.27350","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211047433","article-title":"Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis","author":"Oldham M","year":"2021","unstructured":"Oldham M, Palkimas S, Hedrick A. Safety and efficacy of direct oral anticoagulants in patients with moderate to severe cirrhosis. Ann Pharmacother. 2021, 10600280211047433. 10.1177\/10600280211047433","journal-title":"Ann Pharmacother"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis","volume":"98","author":"Hum J","year":"2017","unstructured":"Hum J, Shatzel JJ, Jou JH, Deloughery TG. The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis. Eur J Haematol. 2017, 98:393-7. 10.1111\/ejh.12844","journal-title":"Eur J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.12788\/fp.0058","article-title":"Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis","volume":"37","author":"Jones K","year":"2020","unstructured":"Jones K, Pham C, Aguilar C, Sheth S. Retrospective review on the safety and efficacy of direct oral anticoagulants compared with warfarin in patients with cirrhosis. Fed Pract. 2020, 37:479-85. 10.12788\/fp.0058","journal-title":"Fed Pract"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13045","article-title":"Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation","volume":"100","author":"Goriacko P","year":"2018","unstructured":"Goriacko P, Veltri KT. Safety of direct oral anticoagulants vs warfarin in patients with chronic liver disease and atrial fibrillation. Eur J Haematol. 2018, 100:488-93. 10.1111\/ejh.13045","journal-title":"Eur J Haematol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli G","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, et al.. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013, 369:799-808. 10.1056\/NEJMoa1302507","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/86348-drug-use-evaluation-of-direct-oral-anticoagulants-doacs-in-patients-with-advanced-cirrhosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:45:49Z","timestamp":1707507949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/86348-drug-use-evaluation-of-direct-oral-anticoagulants-doacs-in-patients-with-advanced-cirrhosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.24029","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,11]]}}}